AT1 2.50% 2.1¢ atomo diagnostics limited

Ann: Access Bio receives FDA clearance for COVID-19 antibody test, page-6

  1. 1,443 Posts.
    lightbulb Created with Sketch. 865
    Great news, this approval will open up several deals including India with DIVOC, Brazil, China and others. COVID antibody testing demand is here to stay over the next decade, especially with new variants and uncertainty around post vaccine immunity.

    I also expect this to fast track their FebriDx kit with Lumos and potentially open up self testing opportunities in the USA.

    Atomo has been brutally sold off, a huge opportunity. I believe Atomo will become a unicorn over the long term. Point of Care, rapid testing and decentralised diagnostics is the future.

    Someone tell our Australian government and pathology lobbyists to get with the program. Routine rapid antigen screening would have prevented Sydney’s latest outbreak.
 
watchlist Created with Sketch. Add AT1 (ASX) to my watchlist
(20min delay)
Last
2.1¢
Change
0.001(2.50%)
Mkt cap ! $13.10M
Open High Low Value Volume
2.0¢ 2.1¢ 2.0¢ $121 6.039K

Buyers (Bids)

No. Vol. Price($)
13 1749919 2.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.1¢ 32000 1
View Market Depth
Last trade - 12.49pm 06/09/2024 (20 minute delay) ?
AT1 (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.